Please login to the form below

Not currently logged in
Email:
Password:

Pomalyst

This page shows the latest Pomalyst news and features for those working in and with pharma, biotech and healthcare.

FDA ‘names and shames’ generic-blocking pharma companies

FDA ‘names and shames’ generic-blocking pharma companies

Pomalyst, followed by Actelion with 26 inquiries mainly for pulmonary artery hypertension drugs Tracleer and Opsumit.

Latest news

  • Celgene’s triple multiple myeloma therapy clears phase III trial Celgene’s triple multiple myeloma therapy clears phase III trial

    Its presence in the field is showing no signs of wavering either, following new data from a pivotal phase III trial of Pomalyst whose results are looking good for Celgene. ... Pomalyst (pomalidomide) - Celgene’s second biggest earner - brought in

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    Celgene is already a big player in blood cancers and haematology with Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide), and buying Juno keeps it in the running for a new generation

  • BMS' Opdivo and Yervoy ace kidney cancer trial BMS' Opdivo and Yervoy ace kidney cancer trial

    The FDA is concerned about the risk associated with combining PD-1/PD-L1 inhibitors such as Keytruda and Opdivo with Celgene's Pomalyst (pomalidomide) or Revlimid (lenalidomide), two widely-used

  • FDA halts third Merck myeloma trial after patient deaths FDA halts third Merck myeloma trial after patient deaths

    More patients taking Merck's drug died than those getting other treatment in the three trials, which all involved combinations of Keytruda with Celgene's Pomalyst (pomalidomide) and Revlimid (lenalidomide), two ... KEYNOTE-183 is testing Pomalyst and

  • Merck suspends two Keytruda trials after patient deaths Merck suspends two Keytruda trials after patient deaths

    Merck suspends two Keytruda trials after patient deaths. Investigators to look at Keytruda with Pomalyst and Revlimid. ... The two trials - KEYNOTE-183 and KEYNOTE-185 - involve combinations of Keytruda with Celgene's Pomalyst (pomalidomide) and Revlimid

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics